AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03646188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
Study NCT02642939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
Study NCT03667300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evogliptin
Description: This group will take daily evogliptin 5mg per oral, not linagliptin.
Study NCT03667300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: This group will take daily linagliptin 5mg per oral, not evogliptin
Study NCT00555425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Buprenorphine/naloxone maintenance (Mtn)
Description: Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
Study NCT00555425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Description: Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
Study NCT01262352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, twice daily every 12 hours (q12h)
Study NCT01262352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral use, twice daily every 12 hours (q12h)
Study NCT00645710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00645710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given via hepatic arterial infusion
Study NCT00645710 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Correlative studies
Study NCT03868566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-612 dose1
Description: Subjects will take dose1 once a day orally for 12 weeks
Study NCT03868566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-612 dose2
Description: Subjects will take dose2 once a day orally for 12 weeks
Study NCT00976391 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide + insulin glargine
Description: albiglutide in combination with insulin glargine
Study NCT00976391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine + preprandial lispro insulin
Description: insulin glargine in combination with preprandial lispro insulin
Study NCT03115658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12 week print based intervention
Study NCT00417729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
Study NCT03687697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media
Description: A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
Study NCT03631121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basalin to Lantus
Description: continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
Study NCT00645710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Description: Correlative studies
Study NCT00645710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies
Study NCT01431846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
Study NCT02975765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
Study NCT03861247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate-binder intervention
Description: Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
Study NCT03861247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate-binder intervention
Description: Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
Study NCT03861247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphorus-restricted dietary intervention
Description: Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
Study NCT01858493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continence promotion group education workshop
Description: Interactive group education workshop promoting continence
Study NCT01858493 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham health lecture
Description: Interactive group education workshop about general health
Study NCT00645710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Description: Given IV
Study NCT04499677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study NCT04499677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir
Description: Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
Study NCT00645710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00005940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV
Study NCT00005940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given PO
Study NCT00005940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00005940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study NCT00005940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study NCT00005940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study NCT00005940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT00005940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00005940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03123588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
Study NCT03123588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagrelide
Description: Anagrelide administered orally at a starting dose of 1 mg BID.
Study NCT03123588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Anagrelide-placebo administered orally BID
Study NCT03123588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ruxolitinib-placebo administered orally BID.
Study NCT01058005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Description: 300 mg intravenous injection every 4 weeks
Study NCT01058005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1a
Description: 44 mcg subcutaneous injection 3 times per week
Study NCT01058005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: 20 mg subcutaneous injection once daily
Study NCT02794805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ¹³C-Octanoate Breath Test
Description: Octanoate Breath Test to be performed on subjects with suspected HCC
Study NCT04767412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise training, inspiratory muscle training
Description: All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
Study NCT00393380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (teriparatide)
Description: Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
Study NCT00927186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
Study NCT00927186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
Study NCT01759641 — intervention group
Intervention type: DEVICE
Intervention: Hypotension-prone patients
Description: Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
Study NCT02053584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario™ Blood Glucose Meter
Description: Each subject will undergo a finger prick and also provide a venous blood sample
Study NCT02053584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI2003
Description: Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
Study NCT00950924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous Vision Bifocal Soft Contact Lenses
Description: Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
Study NCT00950924 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single Vision Soft Contact Lenses
Description: Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
Study NCT01116843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
Study NCT01116843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00299804
Description: PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
Study NCT00949663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline
Study NCT00949663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT00949663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT00949663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT03786575 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing (NGS) detection
Description: The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
Study NCT02852733 — intervention group
Intervention type: OTHER
Intervention: end-of-life emergencies' management
Study NCT01354535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Locked Compression Plate
Description: A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
Study NCT01354535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cable Plating and Strut Allograft with Cerclage Wiring
Description: The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
Study NCT02848352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Study NCT02848352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study NCT02848352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film Sequence
Study NCT02848352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Film Sequence
Study NCT02848352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Film Sequence
Study NCT01556100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ AV-133
Description: A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
Study NCT05391074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: postbiotics (IGENH35.3A)
Description: postbiotics to induce microbiota epigenetic factors
Study NCT04499677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Favipiravir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study NCT04499677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study NCT04499677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study NCT04499677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lopinavir/ Ritonavir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study NCT00714935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Counseling Program (DCP)
Description: An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
Study NCT00714935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coronary Artery Disease Decision Aid
Description: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing.
Study NCT01207479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalaTM
Description: A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
Study NCT01315990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Cetuximab
Description: 1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2
Study NCT02247362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
Study NCT02247362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine Diluent
Study NCT05764096 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03254225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
Study NCT00645710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT00645710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02235727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBR 900
Study NCT02235727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02128100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: * Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
Study NCT05391074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamins (AREDS formulation and recommended daily dose)
Description: vitamins (AREDS to prevent AMD progression
Study NCT02246985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.